Comparative Pharmacology
Head-to-head clinical analysis: KLOR CON versus SLOW K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOR CON versus SLOW K.
KLOR-CON vs SLOW-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
Adults: 600-2400 mg potassium chloride (8-32 mmol K+) orally per day in divided doses, usually 1-2 tablets twice daily. Maximum single dose: 20 mmol. Route: oral. Frequency: 1-4 times daily.
None Documented
None Documented
The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia.
Not applicable; potassium is an electrolyte with no defined elimination half-life; distribution half-life ~2-4 hours
Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant.
Primarily renal (>90%) as potassium ions; minimal biliary/fecal elimination (<5%)
Category C
Category C
Potassium Supplement
Potassium Supplement